13F Holdings
中文EN

KROS Keros Therapeutics, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1664710 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY-83.4%
TTM net income YoY-195.8%
TTM EPS YoY-248.7%
Revenue 3-yr CAGR1,616.0%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-181.3%
Net margin-152.7%
FCF margin-119.4%
EBITDA margin-177.3%

Returns

ROE-12.6%
ROA-11.8%
ROIC (approx.)-389.2%
Asset turnover0.08x

Leverage & solvency

Liabilities / assets9.2%
Debt / equity0.00x
Current ratio18.14x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.78x
Accruals ratio-2.6%
Payout ratio—
Capex / revenue1.0%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$243.86M$0$151,000$0$20.10M
R&D expense$129.64M$173.63M$135.26M$87.27M$55.14M
SG&A expense$46.85M$40.75M$34.83M$27.52M$21.33M
Operating income$67.57M-$210.83M-$169.94M-$114.79M-$56.37M
Interest expense—$0$0$1,000$4,000
Pretax income$91.90M-$187.05M-$152.99M-$104.68M-$56.73M
Income tax$4.88M$300,000$0$0$2.01M
Net income$87.01M-$187.35M-$152.99M-$104.68M-$58.74M
EBITDA$69.08M-$209.60M-$169.13M-$114.12M-$55.99M
EPS (basic)2.34-5.00-5.20-4.15-2.52
EPS (diluted)2.30-5.00-5.20-4.15-2.52
Weighted avg. shares (diluted)37.86M37.44M29.45M25.24M23.33M
Balance sheet
Cash & equivalents$287.42M$561.38M$332.36M$279.05M$231.37M
Receivables$3.57M$2.74M$143,000$0$18.00M
Current assets$315.43M$588.89M$347.29M$285.77M$251.44M
PP&E, net$4.30M$4.24M$4.13M$2.02M$1.33M
Total assets$338.02M$615.89M$370.02M$306.78M$255.25M
Current liabilities$20.41M$27.45M$24.37M$16.55M$11.85M
Total liabilities$34.89M$44.33M$37.81M$29.36M$12.08M
Shareholders' equity$303.13M$571.55M$332.21M$277.42M$243.17M
Shares outstanding19.54M40.55M31.84M27.54M23.97M
Cash flow statement
Operating cash flow$107.50M-$160.87M-$124.51M-$70.06M-$62.15M
Capital expenditure$1.55M$1.93M$2.46M$1.24M$1.02M
Free cash flow$105.95M-$162.80M-$126.97M-$71.30M-$63.17M
Investing cash flow-$1.55M-$1.93M-$2.46M-$1.24M-$1.02M
Financing cash flow-$378.47M$391.82M$178.96M$120.31M$28.55M
Depreciation & amortization$1.51M$1.23M$815,000$674,000$378,000
Stock-based compensation$28.70M$34.87M$28.76M$18.68M$11.72M
Share buybacks$375.00M$0———

Free plan shows the latest 5 periods; Pro shows all 7 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.